Appili Therapeutics
1344 Summer Street
Suite 415
Halifax
Nova Scotia
B3H 0A8
Canada
Tel: 902-442-4655 ext 5551
Website: http://www.appilitherapeutics.com/
About Appili Therapeutics
Appili Therapeutics is developing novel approaches to lead the fight against infectious disease. Despite numerous achievements in the development of anti-infectives, infectious disease remains the leading cause of death worldwide. Many pathogens are becoming increasingly resistant to standard anti-infectives, making treatment difficult or even impossible. The emergence and spread of deadly viruses and antimicrobial resistant bacteria and parasites remain critical threats to human health.
YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Kevin Sullivan, MBA
CFO: Kimberly Stephens
VP, Drug Development: Jamie Doran MSc, DABT, ERT
VP, Business Development: Sean McBride
PIPELINE:
Please click here for Appili Therapeutics' pipeline.
119 articles about Appili Therapeutics
-
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as BioSpace keeps you up to date on all of the FDA's decisions in 2024.
-
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
4/2/2024
Aditxt, Inc. announced that it has entered into a definitive arrangement agreement to acquire Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures.
-
Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia OutbreaksA review of Russian and English literature suggests that Appili’s biodefense program ATI-1701 may have a role in preventing tularemia in Ukraine
3/12/2024
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia.
-
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024
2/13/2024
Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the third quarter of its fiscal year 2024, which ended on December 31, 2023.
-
Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan
12/15/2023
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”) today announced that the United States Patent and Trademark Office (“USPTO”) has published patent claims for ATI-1701 under the U.S. Application No. 16/982,322 filed on September 18, 2020 and titled “A Method for Lyophilizing Live Vaccine Strains of Francisella Tularensis”.
-
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024
11/13/2023
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the second quarter of its fiscal year 2024, which ended on September 30, 2023.
-
Appili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force Academy
10/25/2023
Appili Therapeutics Inc. today announced that the company secured a commitment for the second stage of funding for ATI-1701 from the U.S. Air Force Academy (“USAFA”), who is working in partnership with the Defense Threat Reduction Agency (“DTRA”), the funding agency.
-
Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update
9/28/2023
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, announced the results from its annual meeting of shareholders.
-
Appili Therapeutics Presents at the 10th International Tularemia Conference
9/27/2023
Appili Therapeutics Inc. today announced that Carl Gelhaus, Ph.D., Director of Non-Clinical Research, and key members of Appili’s scientific team, will participate at the 10th International Tularemia Conference, from September 24 to 26, 2023.
-
The FDA on Monday approved the Canadian biopharma’s liquid antibiotic metronidazole, an alternative for patients who are unable to use pills or injections.
-
Appili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral Suspension
9/25/2023
Appili Therapeutics Inc. today announced that its manufacturing and commercialization partner, Saptalis Pharmaceuticals, LLC (“Saptalis”) received approval from the U.S. Food and Drug Administration ("FDA”) for Metronidazole Oral Suspension 500mg/5mL (ATI-1501).
-
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
8/11/2023
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, announced its financial and operational results for the first quarter of its fiscal year 2024, which ended on June 30, 2023.
-
Appili Therapeutics Reports Fiscal Year 2023 Financial and Operational Results
6/23/2023
Appili Therapeutics Inc. today announced its financial and operational results for the fiscal year ended March 31, 2023, and provided an update on the Company’s strategy for fiscal 2024.
-
Appili Therapeutics Announces Issuance of Patent for ATI-1501 Liquid Oral Reformulation of Metronidazole
5/24/2023
Appili Therapeutics Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has published patent claims for ATI-1501 under the U.S. Application No. 18/072,154 filed on November 30, 2022 and titled “ Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same”.
-
Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
4/18/2023
Appili Therapeutics Inc. today announced that Dr. Don Cilla, Appili President and Chief Executive Officer, will present at the Bloom Burton & Co. Healthcare Investor Conference taking place on April 25 and 26, 2023.
-
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer
4/3/2023
Appili Therapeutics Inc., a biopharmaceutical company focused on drug development for infectious diseases and biodefense, announced that it has appointed biopharmaceutical industry veteran Gary Nabors, Ph.D., to serve as Appili’s Chief Development Officer.
-
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023
2/14/2023
Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its financial and operational results for the third quarter of its fiscal year 2023, which ended on December 31, 2022.
-
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program
1/17/2023
Appili Therapeutics has named Dr. Carl Gelhaus as Director of Non-Clinical Research and Arthur Baran as Director of New Product Development for the ATI-1701 program.
-
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole
1/13/2023
Appili Therapeutics Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance of new patent claims for ATI-1501, Appili’s liquid oral reformulation of the antibiotic metronidazole.
-
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
11/14/2022
Appili Therapeutics Inc. today announced that the U.S. Department of Defense (“DOD”), via the Joint Science and Technology Office of the Defense Threat Reduction Agency (“DTRA”) in partnership with the U.S. Air Force Academy (“USAFA”), will provide at least US$14 million in funding over two years to fund the development of ATI-1701.